Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

765 ARTÍCULOS , VIENDO DEL 556 AL 570

Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's disease: a meta-analysis of randomized controlled trials

Marinheiro G, Dantas JM, Mutarelli A, Menegaz de Almeida A, Monteiro GA, Zerlotto DS, Telles JPM.

Neurol Sci. 2024 Oct;45(10):4679-4686. doi: 10.1007/s10072-024-07576-8. Epub 2024 May 20.

Immunotherapy in Alzheimer's disease: focusing on the efficacy of gantenerumab on amyloid-β clearance and cognitive decline

Azargoonjahromi A.

J Pharm Pharmacol. 2024 Sep 3;76(9):1115-1131. doi: 10.1093/jpp/rgae066.

Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer's Disease

Li J, Haj Ebrahimi A, Ali AB.

Int J Mol Sci. 2024 May 9;25(10):5169. doi: 10.3390/ijms25105169.

Integrating a multimodal lifestyle intervention with medical food in prodromal Alzheimer's disease: the MIND-AD(mini) randomized controlled trial

Thunborg C, Wang R, Rosenberg A, Sindi S, Andersen P, Andrieu S, Broersen LM, Coley N, Couderc C, Duval CZ, Faxen-Irving G, Hagman G, Hallikainen M, Håkansson K, Kekkonen E, Lehtisalo J, Levak N, Mangialasche F, Pantel J, Rydström A, Stigsdotter-Neely A, Wimo A, Ngandu T, Soininen H, Hartmann T, Solomon A, Kivipelto M.

Alzheimers Res Ther. 2024 May 30;16(1):118. doi: 10.1186/s13195-024-01468-x.

Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease

Wang HJ, Chinna-Meyyappan A, Feldman OJ, Lanctôt KL.

Expert Opin Emerg Drugs. 2024 Sep;29(3):289-303. doi: 10.1080/14728214.2024.2363215. Epub 2024 Jun 11.

Development of disease-modifying therapies against Alzheimer's disease

Iwatsubo T.

Psychiatry Clin Neurosci. 2024 Sep;78(9):491-494. doi: 10.1111/pcn.13681. Epub 2024 Jun 6.

Therapeutic Effects of Plant Anthocyanin against Alzheimer's Disease and Modulate Gut Health, Short-Chain Fatty Acids

Bayazid AB, Lim BO.

Nutrients. 2024 May 21;16(11):1554. doi: 10.3390/nu16111554.

A Critical Review of Noninvasive Brain Stimulation Technologies in Alzheimer's Dementia and Primary Progressive Aphasia

LoBue C, McClintock SM, Chiang HS, Helphrey J, Thakkar VJ, Hart J.

J Alzheimers Dis. 2024;100(3):743-760. doi: 10.3233/JAD-240230.

Emerging Therapeutic Potential of Fluoxetine on Cognitive Decline in Alzheimer's Disease: Systematic Review

Bougea A, Angelopoulou E, Vasilopoulos E, Gourzis P, Papageorgiou S.

Int J Mol Sci. 2024 Jun 13;25(12):6542. doi: 10.3390/ijms25126542.

The cognitive effect of non-invasive brain stimulation combined with cognitive training in Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis

Yang T, Liu W, He J, Gui C, Meng L, Xu L, Jia C.

Alzheimers Res Ther. 2024 Jun 27;16(1):140. doi: 10.1186/s13195-024-01505-9.

Clinical Pipelines for Alzheimer's Disease Psychosis and Agitation

Oguma T, Jino K.

Chem Pharm Bull (Tokyo). 2024;72(7):610-617. doi: 10.1248/cpb.c23-00416.

Acquired Risk Factors that Influence Risk for Dementia and Possibly Alzheimer Disease

Novak E, Tochtrop M, Schlagel D, Fuller W.

S D Med. 2024 Feb;77(2):87-90.

Somatostatin: Linking Cognition and Alzheimer Disease to Therapeutic Targeting

Sandoval KE, Witt KA.

Pharmacol Rev. 2024 Oct 16;76(6):1291-1325. doi: 10.1124/pharmrev.124.001117.

Longitudinal Trajectories of the Cognitive Function Index in the A4 Study

Amariglio RE, Grill JD, Rentz DM, Marshall GA, Donohue MC, Liu A, Aisen PS, Sperling RA.

J Prev Alzheimers Dis. 2024;11(4):838-845. doi: 10.14283/jpad.2024.125.

Brexpiprazole for Agitation Associated With Dementia Due to Alzheimer's Disease

Lee D, Clark ED, Antonsdottir IM, Porsteinsson AP.

J Am Med Dir Assoc. 2024 Oct;25(10):105173. doi: 10.1016/j.jamda.2024.105173. Epub 2024 Jul 22.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias